Date: 2017-09-22
Type of information: IPO
Company: Krystal Biotech (USA - PA)
Investors:
Amount: $45,54 million
Funding type: IPO
Planned used:
Others:
- • On September 22, 2017, Krystal Biotech, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, announced the closing of its initial public offering of 4,554,000 shares of common stock at a price to the public of $10.00 per share, which includes 594,000 shares of common stock issued upon full exercise by the underwriter of their option to purchase additional shares. Aggregate gross proceeds to Krystal were $45,540,000, before underwriting discounts, commissions and expenses. Krystal’s common stock is traded on the NASDAQ Capital Market under the ticker symbol “KRYS."
- • On September 19, 2017, Krystal Biotech announced the pricing of its initial public offering. The offering was upsized to 3,960,000 shares of common stock at a price to the public of $10.00 per share for aggregate gross proceeds of $39,600,000, before underwriting discounts, commissions and expenses. In addition, Krystal has granted the underwriters a 30-day option to purchase up to an additional 594,000 shares of common stock to cover over-allotments, if any. The Company’s stock is expected to begin trading on the NASDAQ Capital Market (NASDAQ) under the ticker symbol “KRYS” on September 20, 2017. The offering is expected to close on September 22, 2017, subject to customary closing conditions.
- Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS), is acting as sole book-running manager in connection with the offering.
Therapeutic area: Dermatological diseases
Is general: Yes
